News

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting
PM CDT at the ASCO Annual MeetingMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...
Metro International Biotech Announces Initial Dosing in the First Cohort of a Phase 1a Clinical Trial of its Novel NAD Booster MIB-725
Metro International Biotech, LLC (MetroBiotech), an EdenRoc Sciences company that is developing more effective treatments of ...
AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients
AP402 targets p95HER2, a truncated form of HER2 present in 30-40% of HER2-positive cancers, which is associated with exceptionally poor prognosis, and not addressable by conventional anti-HER2 ...
Morningstar3d
Metro International Biotech Announces Initial Dosing in the First Cohort of a Phase 1a Clinical Trial of its Novel NAD Booster MIB-725
Through intelligent medicinal chemistry design and process development ... The ongoing independent Phase 1 clinical trials of MIB-725, as well as the Phase 2 clinical trials of MIB-626, are ...
Morningstar3d
AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients
The Phase 1 clinical trial, currently taking place in Australia ... exclusively in the tumor microenvironment. The antibody design facilitates clustering of HER2 variants to effectively trigger ...